Current Status
Currently nicotine receptor agonist research and drug designing is aimed for treatment of multiple diseases and disorders of the CNS.
Targacept has four drug candidates that are in clinical trials; AZD3480 (TC-1734) for ADHD which is currently in phase II clinical trials and AZD1446 (TC-6683) for Alzheimers disease in collaboration with AstraZeneca, TC-5619 for cognitive dysfunctions in schizophrenia and TC-5214 as an augmentation treatment for major depressive disorder (MDD) in subjects who did not respond adequately to first-line treatment with citalopram hydrobromide.
Memory pharmaceuticals with its partner Roche has one drug candidate, MEM 3454 (RG3487), a partial agonist of the nicotinic alpha-7 receptor, for Alzheimers disease.
Abbott Laboratories in partnership with NeuroSearch have two drug candidates in clinical trials, ABT-894, a selective α4β2 nicotine receptor agonist, for ADHD and ABT-560, a neuronal nicotinic receptor modulator, which was selected by Abbott in 2006 as a new development candidate for cognitive dysfunctions.
EnVivo pharmaceuticals has one drug candidate in clinical trials, EVP-6124, a selective α7 nicotine receptor agonist for Alzheimer’s disease and schizophrenia and one follow-up compound, EVP-4473, that has successfully completed pre-clinical development.
Read more about this topic: Nicotinic Agonist
Famous quotes containing the words current and/or status:
“The current flows fast and furious. It issues in a spate of words from the loudspeakers and the politicians. Every day they tell us that we are a free people fighting to defend freedom. That is the current that has whirled the young airman up into the sky and keeps him circulating there among the clouds. Down here, with a roof to cover us and a gasmask handy, it is our business to puncture gasbags and discover the seeds of truth.”
—Virginia Woolf (1882–1941)
“[In early adolescence] she becomes acutely aware of herself as a being perceived by others, judged by others, though she herself is the harshest judge, quick to list her physical flaws, quick to undervalue and under-rate herself not only in terms of physical appearance but across a wide range of talents, capacities and even social status, whereas boys of the same age will cite their abilities, their talents and their social status pretty accurately.”
—Terri Apter (20th century)